A leading pharmaceutical company with a strong history of developing cardiovascular, diabetes, and vaccine therapies was entering the oncology market with the upcoming launch of a drug designed as a second- or third-line treatment for relapsed/refractory multiple myeloma. The company realized that it had a lot of questions about the audience and hypotheses it needed to validate to ensure proper segmentation and targeting for the new drug.
Read the case study to find out how the pharmaceutical company was able to achieve therapy-related rwd insights and learnings in nine months that would have taken them 12 to 18 months to achieve on its own.
